Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S., including cancer, with one of every three deaths in the country due to CVD and over 2,200 people dying from the disease each day (or an average of one death from CVD every 40 seconds).
Coronary heart disease (CHD), also known as ischemic heart disease, is a form of CVD that is associated with a reduction in blood flow through the vasculature of the heart. Classified under the umbrella of CHD are acute and chronic conditions such as atherosclerosis, angina pectoris, and myocardial infarction (MI). Approximately 15.5 million adults age 20 or older in the U.S. suffer from CHD, which is the single largest cause of death in the U.S. and also is the greatest cause of premature and permanent disability in the labor force (AHA, 2016).
Pink Sheet: global policy and regulatory coverage
02 Aug 2017
Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.
Topics Clinical trials
In Vivo: strategic insights for life sciences decision-maker...
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
Scrip: industry news and insights
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topics Business strategies Drug approval Drug development landscape Drug review
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
You’ll instantly connect to the latest in global medtech developments with industry news, trends, deals, product developments, opinions, analysis, and context behind the headlines and more – all available at your fingertips.
Looking for more products Product Finder
